Colorado Activists File Measures to Legalize Psychedelic Substances
Voters in the state of Colorado may get the chance to vote to legalize the growing and possession of psychedelic substances next year, as well as establish a system of licensed businesses to produce psychedelics such as ibogaine, DMT and psilocybin to be used at healing centers. This comes after New Approach PAC filed a pair of psychedelic reform measures for the state’s 2022 ballot with the secretary of state’s office.
New Approach PAC is a national advocacy group that is behind the medical psilocybin legalization measure that voters in Oregon passed in 2020, as well as a couple of cannabis legalization campaigns in other states.
One of the filed measures would legalize the use of psilocin and psilocybin and allow the substances to be sold and administered in a therapeutic setting. The other broader measure would create a regulatory model for psychedelic therapy in addition to legalizing the growing and possession of various entheogenic substances, including psilocin, psilocybin, mescaline, DMT and ibogaine.
Under this measure, no civil or criminal penalties would be imposed on the possession, use, processing, purchase, transportation or ingestion of natural medicine for individuals aged 21 and above, as long as the substance was less than four grams. Additionally, the state’s Department of Regulatory Agencies would be in charge of creating rules for a psychedelics therapeutic program where individuals aged 21 and above could visit a healing center to obtain treatment.
The text of the broader initiative stipulates that people in the state of Colorado deserve more tools to address mental health conditions, including approaches that are grounded in wellness, health, recovery and treatment such as natural medicines, instead of those grounded in punishment, suffering, stigma and criminalization. The text further notes that natural medicine criminalization has punished individuals for seeking access to medicines that research shows may be effective in treating substance-use disorders, anxiety, depression and suicidality.
This particular proposal would also establish an advisory board that would advise the department on how to implement the regulated access program. In addition, the broader proposal would afford individuals a pathway to have their criminal records expunged for activities related to psychedelics that will be made legal under the reform.
The filing of these proposals comes years after Denver became the first city in the country to decriminalize hallucinogenic mushrooms. Both ballot initiatives have been revised and finalized. Activists currently await approval from the state to begin collecting signatures that will qualify the proposals for the 2022 ballot.
As the wave calling for psychedelic reform gathers momentum, psychedelic companies such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are focused on developing therapeutic formulations from this new group of active pharmaceutical ingredients to meet the needs of people who are yearning for better mental health treatments.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Voters in the state of Colorado may get the chance to vote to legalize the growing and possession of psychedelic substances next year, as well as establish a system of licensed businesses to produce psychedelics such as ibogaine, DMT and psilocybin to be used at healing centers. This comes after New Approach PAC filed a pair of psychedelic reform measures for the state’s 2022 ballot with the secretary of state’s office.
New Approach PAC is a national advocacy group that is behind the medical psilocybin legalization measure that voters in Oregon passed in 2020, as well as a couple of cannabis legalization campaigns in other states.
One of the filed measures would legalize the use of psilocin and psilocybin and allow the substances to be sold and administered in a therapeutic setting. The other broader measure would create a regulatory model for psychedelic therapy in addition to legalizing the growing and possession of various entheogenic substances, including psilocin, psilocybin, mescaline, DMT and ibogaine.
Under this measure, no civil or criminal penalties would be imposed on the possession, use, processing, purchase, transportation or ingestion of natural medicine for individuals aged 21 and above, as long as the substance was less than four grams. Additionally, the state’s Department of Regulatory Agencies would be in charge of creating rules for a psychedelics therapeutic program where individuals aged 21 and above could visit a healing center to obtain treatment.
The text of the broader initiative stipulates that people in the state of Colorado deserve more tools to address mental health conditions, including approaches that are grounded in wellness, health, recovery and treatment such as natural medicines, instead of those grounded in punishment, suffering, stigma and criminalization. The text further notes that natural medicine criminalization has punished individuals for seeking access to medicines that research shows may be effective in treating substance-use disorders, anxiety, depression and suicidality.
This particular proposal would also establish an advisory board that would advise the department on how to implement the regulated access program. In addition, the broader proposal would afford individuals a pathway to have their criminal records expunged for activities related to psychedelics that will be made legal under the reform.
The filing of these proposals comes years after Denver became the first city in the country to decriminalize hallucinogenic mushrooms. Both ballot initiatives have been revised and finalized. Activists currently await approval from the state to begin collecting signatures that will qualify the proposals for the 2022 ballot.
As the wave calling for psychedelic reform gathers momentum, psychedelic companies such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are focused on developing therapeutic formulations from this new group of active pharmaceutical ingredients to meet the needs of people who are yearning for better mental health treatments.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
